Pharma IQ Members

111 results
of 12
February 13, 2018 by Ernan Roman
Ernan
Ernan Roman explores recent research showing that pharma and biotech companies make expensive mistakes by neglecting the power and necessity of customer experience strategies.
Tags:
February 6, 2018 by James Wright
James Wright - Valid Insight
Delving into the common misconceptions surrounding value based pricing and value based payment in pharma.
Tags:
January 3, 2018 by Pharma IQ
Pharma IQ
Download this calendar to view the editorial focus for Pharma and Pharma Logistics IQ for 2018.
Tags:
December 5, 2017 by David B. Sudzus
David B. Sudzus
David B. Sudzus and Russell J. Chibe explore possible outcomes of the Blue Ribbon Commission Report and the Declaration of National Health Emergency regarding the U.S’s Opioid Crisis.
Tags:
November 21, 2017 by Joyce El Hokayem
default profile icon
Human Genetics Scientist, Joyce El Hokayem examines the benefits phytomedicine could offer to today’s healthcare systems and the challenges researchers in this market face
Tags:
October 30, 2017 by Regina Au
Regina Au
While social media is taking the consumer world by storm, the medical industry has been a bit shy to fully embrace these channels because of regulatory requirements.
Tags:
September 26, 2017 by Dr Steven Bradshaw
Dr Steven Bradshaw
Pharma treads a fine line to the tipping point where there is insufficient time to recoup a drug’s costs, due to the number of years left that the patent can run.
Tags:
September 5, 2017 by Pharma IQ
Pharma IQ
As pharma spend continues to climb, so does public scrutiny on drug pricing. Once again, medicine manufacturers are spurred to strike a fair solution to balance raging its R&D appetites with affordable access to treatments for patients
Tags: pharma, medicine, drug, price, prices, spending, disease, treatment, cure, spend, R&D, manufacturers, Big pharma, biotech, small pharma
August 29, 2017 by Dane Hartung
Dane TN
Dane Hartung, Director Marketing and Access, Fougera Pharmaceuticals shares best practices for determining if and when you should implement a new Commercial Patient Access Program. Dane also discusses how you should go about ensuring your patient access program is ethical, compliant and effectively differentiates your product.
Tags:
July 11, 2017 by Pharma IQ
Pharma IQ
Despite some in the market choosing to shut down certain departments, many in the pharma industry are embarking on expansions. Ireland is expected to see a lot of growth
Tags: pharma | medicines | cure | treatment | drug | drug development | research and development | Novo Nordisk | Almac | msd ireland | Shire | Eli Lilly | DHL | Mallinckrodt | J&J | Takeda Pharmaceuticals | Biopharma Engineering
111 results
of 12